ArticleCureus2025
The Association Between 5α-Reductase Inhibitors and the Presence of Subsequent Dry Eye Disease in Androgenetic Alopecia: A TriNetX Database Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose The purpose of this study is to evaluate the association between the application of 5α-reductase inhibitors (5ARI) and the incidence of subsequent dry eye disease (DED) in the androgenetic alopecia population. Method A retrospective cohort study was conducted, and patients with androgenetic alopecia were included and classified according to the receipt of 5ARI therapy or not. A total of 77,982 patients were included in the 5ARI group and the non-5ARI group. The prime outcome was the development of DED after 5ARI usage. The Cox proportional hazard regression was applied for the analysis, which yielded the adjusted hazard ratio (aHR) and 95% confidence interval (CI) of the primary outcome. Results After the whole follow-up period up to 10 years, there were 2317 (2.97%) and 2026 (2.60%) DED episodes in the 5ARI group and the non-5ARI group, respectively. The incidence rate is 1.08 per 1000 person-month and 0.84 per 1000 person-month in the 5ARI group and the non-5ARI group, respectively. The 5ARI group demonstrated a higher incidence of DED episode compared to the non-5ARI group after adjustment (aHR: 1.084, 95% CI: 1.039-1.129, P < 0.001). The cumulative probability of the DED development was also significantly higher in the 5ARI group than the non-5ARI group (P < 0.001). In the sensitive analysis, the DED incidences were significantly higher in the 5ARI population than in the non-5ARI population, with several characteristics such as the metabolic syndromes. Conclusions The application of 5ARI is associated with a higher risk of following DED development, which is related to the application time in the androgenetic alopecia population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.